FDA
-
-
-
-
-
-
-
ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older
-
-
-
-
-
-
-
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative
-
-
-
-
-
-
-
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025
-
-
-
-
-
-
-
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
-
-
-
-
-
-
-
ADMA Biologics to Participate in the J.P. Morgan Healthcare Conference on January 13, 2025
-
-
-
-
-
-
-
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
-
-
-
-
-
-
-
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
-
334,274 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


